Aug 17, 2026 · 6 min
Drug setbacks and copper demand reshape European stock moves
AstraZeneca Climbs, Glencore Rises, Argenx Surges
The episode connects sharp biotech and mining-market reactions with the infrastructure pressures driving smarter, faster-growing cities.
- 1AstraZeneca fell after discontinuing a Phase 3 lung-cancer drug trial, underscoring the market impact of development setbacks.
- 2Glencore rose as a South Korean financing deal and copper demand linked to AI infrastructure supported its shares.
- 3Argenx surged on positive late-stage myositis results before the discussion broadens to AI-enabled urban planning in Dubai.
Don't miss
Argenx’s positive late-stage myositis results produce a sharp rally and crystallize why biotech shares can move dramatically on trial outcomes.
The brief
The episode opens with a question about whether rapidly growing cities can build smarter systems fast enough, using Dubai as a central example.
Bloomberg reporter Kit Rees examines AstraZeneca’s decline after the company discontinued a Phase 3 lung-cancer drug trial, showing how clinical setbacks can quickly reset expectations.
Glencore’s rise is tied to a $1 billion South Korean financing deal connected to copper supplies, while AI data centers, electrification, and power infrastructure strengthen the demand story.
Argenx delivers the sharpest biotech move: positive late-stage results for an experimental myositis treatment send shares higher and illustrate the binary nature of drug development.
The closing smart-cities discussion widens the frame, asking how artificial intelligence, long-term planning, and infrastructure investment can keep pace with urban population growth.
What was said on this episode
11 statements · 6 positive · 1 negative · 2 mixed · 2 neutral
AstraZeneca shares remain depressed since July
“AstraZeneca shares are pretty depressed since July”
Listen at 1:26
AstraZeneca shares may be experiencing a modest rebound
“it could just be rebounding a little bit”
Listen at 1:35
London copper prices are approaching a record high
“copper prices in London coming close to a record high”
Listen at 1:53
Mining stocks closely track metals prices
“They really track metals prices really closely.”
Listen at 1:59
AI has been the major driver of copper demand this year
“AI has been the big demand driver this year.”
Listen at 2:05
Copper demand is currently very high
“there's just a huge demand for copper right now”
Listen at 2:17
Recent positive developments are pushing Glencore shares higher
“all this good news is just pushing the shares higher today”
Listen at 2:33
Biotech stocks depend heavily on individual drug-development success
“biotech stocks, they can be a little bit binary because their fortunes really depend on whether a particular drug is successful in its development”
Listen at 2:59
Biotech shares can experience very large price swings
“you can see some really, really big swings in the shares there”
Listen at 3:09
Argenx shares are up about 10%
“its shares are now positive on the air that up about 10%”
Listen at 3:13
Biotech drug-development outcomes are roughly evenly balanced
“it's a sort of 50-50 chance of things working out, really”
Listen at 3:18
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Bloomberg L.P.Books & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.